文章：

分子靶向诊疗在放射性碘难治性分化型甲状腺癌中的应用

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

原文发布日期：27 August 2023

DOI: 10.3390/cancers15174290

类型: Article

开放获取: 是

英文摘要：

Differentiated thyroid cancer (DTC) is the most common subtype of thyroid cancer and has an excellent overall prognosis. However, metastatic DTC in certain cases may have a poor prognosis as it becomes radioiodine-refractory. Molecular imaging is essential for disease evaluation and further management. The most commonly used tracers are [18F]FDG and isotopes of radioiodine. Several other radiopharmaceuticals may be used as well, with different diagnostic performances. This review article aims to summarize radiopharmaceuticals used in patients with radioiodine-refractory DTC (RAI-R DTC), focusing on their different molecular pathways. Additionally, it will demonstrate possible applications of the theranostics approach to this subgroup of metastatic DTC.

摘要翻译： 

分化型甲状腺癌（DTC）是甲状腺癌最常见的亚型，总体预后良好。然而，部分转移性DTC可能因发展为放射性碘难治性而预后不良。分子影像学对于疾病评估和后续管理至关重要。最常用的示踪剂为[18F]FDG和放射性碘同位素，此外还可使用多种具有不同诊断性能的放射性药物。本文旨在综述放射性碘难治性DTC（RAI-R DTC）患者诊疗中使用的放射性药物，重点关注其作用的不同分子通路，并探讨诊疗一体化策略在该转移性DTC亚群中的潜在应用前景。

原文链接：

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer